A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/17 (2006.01) A61K 31/7088 (2006.01) A61K 39/00 (2006.01) A61P 37/00 (2006.01) G01N 33/564 (2006.01)
Patent
CA 2525966
Epitopic fragments of Nogo, including Nogo 45-66, elicit a specific and strong T cell response, and a B cell response. T cells reactive to Nogo antigens are capable of ameliorating ongoing disease, which may be induced with other antigens. The present invention provides compositions and methods for the identification and use of Nogo epitopic fragments in the treatment of immune related disease.
Les fragments d'épitopes de Nogo, dont le Nogo 45-66, provoquent une réponse spécifique et forte des cellules T et des cellules B. Les cellules T réagissant aux antigènes de Nogo sont capables d'améliorer des maladies en cours pouvant avoir été induites par d'autres antigènes. L'invention porte sur des compositions et méthodes d'identification et d'utilisation de fragments d'épitopes de Nogo pour le traitement de maladies immunitaires.
Fontoura Paulo
Garren Hideki
Steinman Lawrence
Bayhill Therapeutics Inc.
Smart & Biggar
The Board Of Trustees Of The Leland Stanford Junior University
LandOfFree
Novel immunomodulating peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel immunomodulating peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel immunomodulating peptide will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1378186